logo-loader
viewPolarean Imaging PLC

University of Kansas Medical Center orders another of Polarean’s 9820 Xenon Polariser systems

The hyperpolarised 129-Xenon gas helps to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function

polarean's Xenon Polariser system
25 of Polarean’s polarisers are now either installed or on order

The University of Kansas Medical Center (KUMC) has placed an order for another of Polarean Imaging PLC’s (LON:POLX) 9820 Xenon Polariser system.

KUMC is a major research and teaching hospital and this polariser will form the cornerstone of a new hyperpolarised 129Xe imaging research programme.

WATCH: Polarean on track to complete enrolment for phase III trials

Following receipt of this latest order, Polarean now has a total of 25 polarisers either installed or on order.

“We are delighted to begin our relationship with KUMC and look forward to a long and mutually beneficial work programme which will aim to expand the clinical and public health frontiers of hyperpolarised xenon imaging,” said chief executive Richard Hullihen.

Better MRI scans

MRI scans generally aren’t very useful in assessing lung function, but Polarean is trying to change that. The company has developed a drug-device combination which uses hyperpolarised 129-Xenon gas MRI.

By inhaling and holding a small amount of the gas for just a few seconds, the patient is able to create a much stronger MRI signal, providing doctors with multiple images of lung structure and function.

Polarean, which is looking to sell the gas, the instrument which polarises the gas, and an associated quality assurance device, kicked off a trial of the technology last summer in two sites: Duke University and the University of Virginia and at the University of Cincinnati in June.

The trial is a 'head-to-head' non-inferiority trial testing 129Xe MRI against 133-Xenon (133Xe) scintigraphy.

In morning trading, Polarean shares were 4% higher at 20.80p.

 -- Adds share price --

Quick facts: Polarean Imaging PLC

Price: 19.5 GBX

AIM:POLX
Market: AIM
Market Cap: £22.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Polarean Imaging PLC named herein, including the promotion by the Company of Polarean Imaging PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Polarean Imaging eagerly awaiting readouts from its key phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen speaks to Proactive London's Andrew Scott following the news they've now completed patient enrolment for the phase III clinical trials of its MRI lung scan technology. He says the trials are now in the image and statistical analysis stage, a...

5 days, 14 hours ago

2 min read